NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free LENZ Stock Alerts $16.24 +0.52 (+3.31%) (As of 11:27 AM ET) Add Compare Share Share Today's Range$15.69▼$16.3650-Day Range N/A52-Week Range$14.07▼$29.82Volume148,760 shsAverage Volume64,126 shsMarket Capitalization$59.28 millionP/E RatioN/ADividend YieldN/APrice Target$31.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get LENZ Therapeutics alerts: Email Address LENZ Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.3% Upside$31.33 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$15 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.27 out of 5 starsMedical Sector318th out of 915 stocksBiological Products, Except Diagnostic Industry41st out of 155 stocks 4.5 Analyst's Opinion Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for LENZ. Previous Next 0.0 Dividend Strength Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LENZ. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows6 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,000,075.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of LENZ Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENZ Therapeutics is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About LENZ Therapeutics Stock (NASDAQ:LENZ)LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More LENZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LENZ Stock News HeadlinesApril 21, 2024 | americanbankingnews.comCritical Survey: LENZ Therapeutics (LENZ) and Its CompetitorsApril 18, 2024 | morningstar.comLENZ Therapeutics IncApril 29, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 14, 2024 | morningstar.comLENZ Therapeutics Inc LENZApril 10, 2024 | nasdaq.comLENZ Therapeutics, Inc. Common Stock (LENZ)April 10, 2024 | markets.businessinsider.comBlindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst SaysApril 3, 2024 | reuters.comLenz Therapeutics' eye disease drugs meet main goal of late-stage studyApril 3, 2024 | businesswire.comLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsApril 29, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 2, 2024 | businesswire.comLENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsMarch 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOSee More Headlines Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$31.33 High Stock Price Target$34.00 Low Stock Price Target$28.00 Potential Upside/Downside+99.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($15.6054) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-27.96% Debt Debt-to-Equity RatioN/A Current Ratio39.20 Quick Ratio39.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.06 per share Price / Book0.71Miscellaneous Outstanding Shares3,650,000Free Float2,248,000Market Cap$57.38 million OptionableN/A Beta0.20 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Evert B. Schimmelpennink (Age 52)President, CEO, Secretary & Director Comp: $886.54kMr. Shawn Olsson (Age 41)Chief Commercial Officer Comp: $532.13kMr. Marc G. Odrich M.D. (Age 65)Chief Medical Officer Comp: $576.95kMr. James W. McCollum (Age 69)Co-Founder & Director Mr. Gerald HornSenior Scientific Advisor & FounderMr. Daniel R. Chevallard CPA (Age 44)Chief Financial Officer Mr. Domenick PorfidiaVice President of SalesMr. David MurphySenior Director of Marketing & Alliance DevelopmentMr. Marvin J. Garrett (Age 73)Senior Vice President of Regulatory & Quality More ExecutivesKey CompetitorsCidara TherapeuticsNASDAQ:CDTXEntera BioNASDAQ:ENTXAligos TherapeuticsNASDAQ:ALGSAVROBIONASDAQ:AVROIkena OncologyNASDAQ:IKNAView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 63,916 shares on 4/25/2024Ownership: 1.751%Ra Capital Management, L.P.Bought 998,009 shares on 3/21/2024Total: $15.00 M ($15.03/share)View All Insider TransactionsView All Institutional Transactions LENZ Stock Analysis - Frequently Asked Questions Should I buy or sell LENZ Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LENZ Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LENZ shares. View LENZ analyst ratings or view top-rated stocks. What is LENZ Therapeutics' stock price target for 2024? 5 brokerages have issued twelve-month target prices for LENZ Therapeutics' shares. Their LENZ share price targets range from $28.00 to $34.00. On average, they anticipate the company's stock price to reach $31.33 in the next year. This suggests a possible upside of 97.3% from the stock's current price. View analysts price targets for LENZ or view top-rated stocks among Wall Street analysts. How have LENZ shares performed in 2024? LENZ Therapeutics' stock was trading at $16.20 on January 1st, 2024. Since then, LENZ stock has decreased by 2.0% and is now trading at $15.88. View the best growth stocks for 2024 here. When is LENZ Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LENZ earnings forecast. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BML Capital Management LLC (1.75%). View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LENZ) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
